Curriculum Vitae

Name: Keyang Xu (徐渴陽) **Phone number:** +853 66934882 **Email:** kyxu@must.edu.mo

Gender: Male **DOB:** 1993.05.31

Present academic position:

Assistant Professor, 2025.01-present

School of Chinese Medicine, The Macau University of Science and Technology

PhD supervisor for Chinese medicine, Integrated Chinese medicine, and Biological science

MUST scholar database: https://scholar.must.edu.mo/scholar/107295;

ORCID: https://orcid.org/0000-0002-7049-2528; H index=17

The teaching curriculum covers Western Internal Medicine, Physiology, Pathology, Advances in Integrative Chinese and Western Medicine, Cell Biology, Pharmacology of Chinese Materia Medica, Modern Biotechnology, and Scientific Literature Retrieval and Academic Writing.

Research Interests

1. Developing an extracellular vesicle-based targeted drug delivery system;
2. Exploring the interaction between metabolic diseases and malignant tumors based on multi-omics and extracellular vesicles;
3. Discovering the complex mechanism between malignant tumors and neurons;
4. Pharmacological effects and active components of traditional Chinese medicine against metabolic diseases & cancer.

Academic qualifications

Doctor of Philosophy, 2021.9-2024.10

School of Chinese Medicine, Hong Kong Baptist University

Supervisor: Prof Hiu Yee Kwan

Co-supervisor: Prof Aiping Lyu (Academia Europaea Fellow)

Master of Integrated Traditional Chinese and Western Clinical Medicine, 2016.9-2019.6

School of Clinical Medicine, Zhejiang Chinese Medical University

Supervisor: Prof Jianfeng Bao (Hangzhou Xixi Hospital)

Co-supervisor: Prof Liang Qiao (Storr Liver Centre, The University of Sydney)

Bachelor of Integrated Traditional Chinese and Western Clinical Medicine, 2011.9-2016.6

School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine

Previous academic positions

Visiting scholar, 2024.05-2024.11

Storr Liver Centre, Westmead Hospital, The University of Sydney
Supervisor: Prof Liang Qiao
Co-supervisor: Prof Jacob George（Australian Academy of Health & Medical Sciences Fellow）
Research Assistant, 2020.9-2021.08
School of Chinese Medicine, Hong Kong Baptist University
Physician, 2019.8-2020.8
Hangzhou Binjiang LvKang Hosipital

Research grants

1. Investigating the efficacy of the dose-rich components of Huoxue Tongfu Formula on postoperative abdominal adhesions based on macrophage metabolic reprogramming – Macau Science and Technology Development Fund (No. 0021/2022/A3), 1,617,000 MOP, **Principal Investigator, ongoing**.
2. Mechanism of fatty hepatocyte-derived exosomal protein CPN2 mediating zinc homeostasis to promote hepatocellular carcinoma growth – National Natural Science Foundation of China (Young Scientist Program, Category C) (No. 82503193), 300,000 RMB, **Principal Investigator, ongoing**.
3. Mechanism of exosomal protein CPN2 in promoting steatohepatitis-associated hepatocellular carcinoma growth and preclinical exploration of its inhibitor Q-2729 – Macau Science and Technology Development Fund (No. 0107/2025/ITP2), 403,100 MOP, **Principal Investigator, ongoing**.
4. Mechanism of apigenin-mediated ECM1 protein degradation inhibiting triple-negative breast cancer progression – Macau University of Science and Technology Research Fund (No. FRG-25-078-FC), 100,000 MOP, **Principal Investigator, ongoing**.
5. WNT974 and artesunate exhibit synergy in inhibiting colorectal cancer growth by increasing KRAS protein degradation – Medical Health Research Foundation of Hong Kong SAR (No. 08193596), Co-Investigator, completed.
6. The role of adipose tissue-derived exosomes in high-fat diet-enhanced colorectal cancer metastasis – HKBU Initiation Grant for Faculty Niche Research Areas (No. RC-FNRA-IG/2021/SCM/01), Co-Investigator, completed.
7. Exploring the mechanism of adipocyte exosome-derived ARF1/MAP3K in hepatic fibrosis – Guangdong Natural Science Foundation (No. 2023A1515011811), Co-Investigator, ongoing.
8. Global proteomic study of adipose tissue-derived exosomes from different depots to elucidate their effects on obesity – Shenzhen Science and Technology Innovation Bureau Project (No. #2021Szvup131), Co-Investigator, completed.
9. Mechanism of LncBRM-mediated RBMY1A1 protein promoting hepatocellular carcinoma progression and metastasis in males – Zhejiang Natural Science Foundation (No. LSY19H030002), Co-Investigator, completed.
10. Clinical diagnostic value of CHI3L1 in chronic hepatitis B patients with abnormal ALT and in carriers – Zhejiang Medical Association (No. 2019KY532), Co-Investigator, completed.

Most presentative papers (*equal contribution，#Correspondence author)

1. **Xu KY**, Fu A, Li ZY, Miao LB, Lou ZH, Jiang KY, Lau C, Su T, Tong TJ, Bao JF, Lyu AP, Kwan HY. Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. ***Nat Commun.*** 2024; 15, Article number: 1685. **（IF=15.7, Citation 31）**

Highlights: In obesity, circulating small extracellular vesicles (sEVs) carry increased levels of ECM1 protein in an integrin-β2-dependent manner, and these sEVs deliver ECM1 to breast cancer (BC) cells, promoting their invasion and migration. Delivery of ECM1 via sEVs from obese mice upregulates MMP3 and S100A/B in BC cells, thereby enhancing tumor growth and metastasis in vivo, revealing a mechanistic link between obesity and BC progression and suggesting sEV-based therapeutic strategies. **Based on these**, we identified **Apigenin, a natural compound,** which could degrade the ECM1 protein in BC cells; then we loaded the apigenin into PD1-engineering sEVs for targeting TNBC for therapeutic strategies (The manuscript is under review in Advanced Healthcare Materials).

2. Jia BQ, Zhao LY, Tang MH, Xie NB, Huang YQ, Liang XX, Yang GH, Wu QB, Sun ZG, Kwan HY#, Sun H#, **Xu KY#**. Neuron–Tumor Crosstalk in Cancer: Molecular Mechanisms and Translational Advances. ***Molecular Cancer***, 2026. https://doi.org/10.1186/s12943-026-02715-5 **(IF=42.25）**

Highlights: Tumor neuron hijack is a malignant adaptive program in which tumor cells recruit and functionally reprogram the nervous system to sustain growth, invasion, metastasis, immune escape, and treatment resistance while also driving cancer-associated pain—a debilitating host response that further promotes tumor progression. This process involves context-dependent strategies (synaptic integration in CNS tumors vs. de novo innervation in peripheral tumors) and a tripartite crosstalk among nerves, immune cells, and tumor cells that establishes an immunosuppressive microenvironment, offering therapeutic opportunities via neural-signal reprogramming, synaptic blockade, and combination with immunotherapy.

3. Yang YQ, Qi JC, Lang YQ, Wu ML, Gu YX, Lu XY, Wang MS, Wu QB, Chu Fh#, Cai Mr# & **Xu KY#.** Injectable multi-component hydrogels for the treatment of ascites caused by hepatocellular carcinoma via anti-tumor and reduction of ascites generation. ***J. Nanobiotechnology***.2026, January 21. **（IF=12.6）**

Highlights: Inspired by eighteen incompatible medicaments from Chinese medicine, we developed an injectable multi-component hydrogel (GK-GA) from **herbal medicine, Genkwa Flos and glycyrrhizic acid** that demonstrated potent anti-ascitic efficacy in hepatocellular carcinoma, reducing ascites formation by 47.62% at 6.25 mg/kg. Multi-omics mechanistic studies revealed that the GK-GA hydrogel exerts dual therapeutic effects against malignant ascites: promoting tumor cell apoptosis via mitochondrial ROS elevation and PI3K-AKT modulation, while suppressing ascites formation by normalizing the aldosterone metabolic pathway.

4. **Xu KY**, Qibiao Wu, Zhao Lingyun, Romario Nguyen, Fatema Safri, William Yang, Yikun Xu, Yun Ye, Hiu Yee Kwan, Qiang Wang, Xiuming Liang, Muhammad J.A. Shiddiky, Majid E. Warkiani, Jacob George, Liang Qiao, Jianfeng Bao. Extracellular vesicles as a promising platform of precision medicine in liver cancer. ***Pharma Res***, Volume 217, 2025, 107800. **（IF=10.5）**

Highlights: Extracellular vesicles (EVs) are natural carriers of biological information and play pivotal roles in intercellular communication. EVs are biocompatible, have low immunogenicity, and are capable of traversing biological barriers, making them ideal tools for disease diagnosis and therapy. Despite their promising prospects, the full realization of EVs potential faces several challenges. This article aims to comprehensively review the biological and molecular features of EVs, their applications in liver cancer and possible underlying mechanisms, and the critical challenges affecting the clinical translation of EVs-based therapies in liver cancer.

5. **Xu KY**, Kwan, Hiu Yee, Wang, Jue. Integration of individual sEV with single-cell analysis to reveal association of immune cell subsets with chemotherapy response in breast cancer. **Journal of Clinical Oncology**[0732-183X], Published 2026, Volume 44, Issue 16_suppl, Pages e13114. (**IF=43.4**）

Highlights: Integrating multi-omic data from single-entity sEV surface proteins and single-cell RNA-seq reveals that the ITGB2-ICAM1 ligand-receptor interaction between breast cancer-derived sEVs and macrophages triggers VCAM1 release from macrophages, which promotes doxorubicin resistance in breast cancer. Neutralizing anti-ICAM1 antibody abolishes VCAM1 induction and restores chemosensitivity in mouse models, while the study also demonstrates a novel multimodal alignment strategy that integrates distinct high-dimensional datasets to identify functional sEV-cell binding pairs. The abstract was accepted by the American Society of Clinical Oncology 2026 Annual meeting, which is being submitted to the prestigious journals.

List for other publications (*equal contribution，#Correspondence author)

6. Ma X, Zheng W, Wu C, Xu C, Ji X, **Xu KY#**, Yin Q#. Roles of Extracellular Vesicle-Derived microRNAs in Metabolic Dysfunction-Associated Steatotic Liver Disease to Hepatocellular Carcinoma. ***Biomedicines***. 2026 Feb 26;14(3):528. **(IF=3.9）**
7. Ye, C.*, **Xu, KY**.*, Lan, X. et al. Navigating thyroid hormone signaling in liver fibrosis: mechanisms and clinical implications. ***J Endocrinol Invest*** (2026). **(IF=3.5）**
8. Jiang K, Bao J, Lou Z, Liu F, **Xu KY#**, Kwan HY#. An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis. ***Pharmaceuticals***. 2025; 18(2):227. **(IF=4.8）**
9. Zhao L, Guo R, Zhao Z, Wang J, Zhou H#, Wu Q#, **Xu KY#**. Linking Hyperuricemia to Cancer: Emerging Evidence on Risk and Progression. ***Curr Oncol Rep*** **27**, 703–716 (2025). **(IF=5）**
10. Zheng W., Xu C., Yin Q., Huang Y., Zhou H., Shen G., **Xu KY#**, & Wang S#. (2025). Prognostic potential of polyamine metabolism-related genes in hepatocellular carcinoma. Scientific reports, 15(1), 23648. **(IF=3.9）**
11. Xu C, Zhao L-Y, Ye C-S, Xu KC# and **Xu KY#**. The application of machine learning in clinical microbiology and infectious diseases. ***Front. Cell. Infect. Microbiol***.2025, 15:1545646. **(IF=4.8）**
12. Lin, Q. N., Wu, Q., Lv, C., Tang, J., Zhao, L. Y., & **Xu KY#**. Potential role of coagulation markers in early detection of bone metastasis in gastric cancer: A critical review. ***World J Gastrointest Oncol***., 2025, *17*(3), 100292. **(IF=4.8）**
13. Guo X, Asthana P, Gurung S, Zhang S, Wong SKK, Fallah S, Chow CFW, Che S, Zhai L, Wang Z, Ge X, Jiang Z, Wu J, Zhang Y, Wu X, **Xu KY**, Lin CY, Kwan HY, Lyu A, Zhou Z, Bian ZX, Wong HLX. Regulation of age-associated insulin resistance by MT1-MMP-mediated cleavage of insulin receptor. ***Nat Commun***. 2022 Jun 29;13(1):3749. **(IF=14.919）**
14. Li Y, Wang J, Huang C, Shen M, Zhan HK#, **Xu KY#**. RNA N6-methyladenosine: a promising molecular target in metabolic diseases. ***Cell Biosci***. 2020 Feb 21; 10:19. Review **(IF=7.133）**
15. Zhou ZW, Zheng W, Xiang Z, Ye CS, Yin QQ, Wang SH, Xu CA, Wu WH, Hui TC, Wu QQ, Zhao LY, Pan HY#, **Xu KY**#. Clinical implications of exosome-derived noncoding RNAs in liver. ***Lab Invest.*** 2022 May;102(5):464-473. **Review (IF=5.662)**
16. **Xu KY**, Liu SR, Zhao X, Zhang X, Fu X, Zhou Y, Xu KC, Miao L, Li Z, Li Y, Qiao L, Bao JF. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. ***Biomed Pharmacother.*** 2019 Feb;110: 844-849. **(IF=3.457）**

17. **Xu KY**, Zhao X, Fu X, Xu KC, Li Z, Miao L, Li Y, Cai Z, Qiao L, Bao J. Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. ***Biomed Pharmacother***. 2019 Sep; 117:109158. **(IF=4.545）**
18. Xu KC, Sun Y, Sheng B, Zheng Y, Wu X, **Xu KY**[#]. Role of identIFied RNA N6-methyladenosine methylation in liver. **Anal Biochem**. 2019 Aug 1; 578:45-50. Review **(IF=2.877）**
19. Zhu L, Zhao LY, Wang Q, Zhong S, Guo XM, Zhu Y, Bao JF[#], **Xu KY**[#], Liu SR[#]. Circulating exosomal miRNAs and cancer early diagnosis. ***Clin Transl Oncol***. 2022 Mar;24(3):393-406. Review **(IF=3.405）**
20. Lou ZH, **Xu KY**, Qiao L, Su XQ, OuYang Y, Miao LB, Liu F, Wang Y, Fu A, Ren XH, Huang JS, Li ZY, Bao JF. Diagnostic Potential of the Serum lncRNAs HOTAIR, BRM and ICR for Hepatocellular Carcinoma. ***Front Biosci (Landmark Ed)*** 2022, 27(9), 264. **(IF=3.115）**
21. Li Y, **Xu KY**, Xu KC, Chen S, Cao Y, Zhan H. Roles of IdentIFied Long Noncoding RNA in Diabetic Nephropathy. ***J Diabetes Res***. 2019 Feb 12; 2019:5383010. **(IF=3.04）**
22. Cai Z, **Xu KY**, Li Y, Lv Y, Bao J, Qiao L. Long noncoding RNA in liver cancer stem cells. ***Discov Med***. 2017 Sep;24(131):87-93. PMID: 28972877. **(IF=2.4）**
23. Liu, MX, Cai, YT, Yang, Y, Zhao, ZM, Wang, J, Xu, KY, Liu, YX, Wu, QB. Tumor Cell Membrane-Coated Oxygen-Evolving Carbon Nitride Nanozymes Combined with Curcumenol Delivery for Lung Cancer Therapy via 'Open-Source Throttling' Strategy. Advanced Healthcare Materials, 2025, 2192-2640. (**IF=9.6**）
24. Chen B-d, Zhao Y, Wu J-l, Zhu Z-g, Yang X-d, Fang R-p, Wu C-s, Zheng W, Xu C-a, **KY Xu**, et al. Exosomes in Skin Flap Survival: Unlocking Their Role in Angiogenesis and Tissue Regeneration. *Biomedicines*. 2025; 13(2):353. (**IF=3.9**）
25. Wang H., Li Y., Fan K, **KY Xu,** et al. Global Epidemiology of Early-Onset Aortic Aneurysm: Temporal Trends, Risk Factors, and Future Burden Projections. J Epidemiol Glob Health 2025;15, 25 . (**IF=3.1**）
26. Qiang Wang, Henrik Nilsson, **KY Xu**, Xufu Wei, Danyu Chen, Dongqin Zhao, Xiaojun Hu, Anrong, Wang, Guojie Bai. Exploring tumor heterogeneity in colorectal liver metastases by imaging: Unsupervised machine learning of preoperative CT radiomics features for prognostic stratification. ***European Journal of Radiology.*** 2024, 175, 111459. (**IF=3.09**）
27. Di H, Wang S, Xu C, Yin Q, **Xu KY**, Zheng W. Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease. ***Glob Heart***. 2024 Nov 26;19(1):88. **(IF=3.0）**
28. Yajing He, Cunsi Ye, **Xu KY**, Lili Yang, Kaile Wang, Xiaomei Wang, Meiyu Li, Yu Wu, Qisu Ying, Ming Wang, Shijian Quan and Xiu Yang. Risk Factors and Survival Analysis of Haemodialysis Complicated with Infective Endocarditis. ***Exp Ther Med***. 2023, 25(5): 1-8. **(IF=2.751）**
29. Fan X, Meng M, Li B, Chen H, Tan J, **Xu KY**, Xiao S, Kwan HY, Liu Z, Su T. Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay. ***J Transl Med***. 2023 Apr 16;21(1):260. **(IF=7.40）**
30. Chen M, Zhang F, Chen B, Lau C, **Xu KY**, Tong T, Huo C, Han Q, Su T, Kwan HY. Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots. ***Cell Mol LIFe Sci***. 2022 Oct 28;79(11):570. **(IF=9.261）**
31. An L, Zhang M, Lin YF, Jiang T, **Xu KY**, Xiao SL, Cai LM, Kwan HY, Liu ZQ, Su T. Morroniside, a novel GATA3 binding molecule, inhibits hepatic stellate cells activation by enhancing lysosomal acid lipase expression. ***Phytomedicine***. 2022-08. **(IF=6.656）**
32. Zheng W, Shen GL, **Xu KY**, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. ***World J Gastrointest Oncol***. 2022 Jan 15;14(1):253-264. **(IF=3.393）**

33. Kwan HY, Chen MT, **Xu KY**, Chen BS. The impact of obesity on adipocyte-derived extracellular vesicles. ***Cell Mol LIFe Sci***. 2021 Dec;78(23):7275-7288. Reivew **(IF=9.261）**
34. Hu X, Fatima S, Chen MT, **Xu KY**, Huang CH, Gong RH, Su T, Wong HLX, Bian ZX, Kwan HY. Toll-like receptor 4 is a master regulator for colorectal cancer growth under high-fat diet by programming cancer metabolism. ***Cell Death Dis***. 2021 Aug 12;12(8):791. **(IF=8.469）**
35. Xu BJ, Wang L, Zhan HK, Liangbin Zhao, Yuehan Wang, Meng Shen, **Xu KY**, Li Li, Xu Luo, Shasha Zhou, Anqi Tang, Gang Liu, Lu Song, Yan Li. Investigation of the Mechanism of Complement System in Diabetic Nephropathy via Bioinformatics Analysis. ***J Diabetes Res***. 2021. **(IF=4.061）**
36. Yan Li, Lei Wang, Bojun Xu, Liangbin Zhao, Li Li, **KY Xu**, Anqi Tang, Shasha Zhou, Lu Song, Xiao Zhang, Huakui Zhan. Based on Network Pharmacology Tools to Investigate the Molecular Mechanism of Cordyceps sinensis on the Treatment of Diabetic Nephropathy. ***J Diabetes Res***, 2021. **(IF=4.061）**
37. Liu S, Guo R, Hou X, Zhang Y, Jiang X, Wang T, Wu X, **Xu KY**, Pan X, Qiao L. Adipose-tissue derived porcine mesenchymal stem cells efficiently ameliorate CCl4-induced acute liver failure in mice. ***Cytotechnology***. 2020 Jun;72(3): 327-341. **(IF=2.058）**
……

Scholarships and Awards

Researcher scholarship of the International Society of Extracellular Vesicles Annual Meeting，2024
Hong Kong Baptist University Transdisciplinary Scholarship, 2022
Bronze Award (3rd place) in the 6th Zhejiang Province Internet plus Challenge Cup, 2021
Top Ten Academic Stars of Zhejiang Chinese Medical University, 2020
……

Academic Services

The Specialty Committee of Dose-Effect Relationship of Prescriptions and Medicinals, World Federation of Chinese Medicine Societies (WFCMS) **Executive Director**
The Specialty Committee of Clinical Pharmacy of Chinese Medicine, China Association of Chinese Medicine Information **Executive Director**
The Specialty Committee of Endocrinology, World Federation of Chinese Medicine Societies (WFCMS) **Council Member**
The Specialty Committee of Immunology of Chinese Medicine, World Federation of Chinese Medicine Societies (WFCMS) **Council Member**
Asia Pacific Societies for Extracellular Vesicles **Member**
American Society of Clinical Oncology **Member**
Macau Higher Education Development Promotion Association **Member**
The Good Practice in Traditional Chinese Medicine Research Association **Member**
Student networks on EVs **Member**
Frontiers in Nutrition **Associate Editor**
Frontiers in Oncology **Associate Editor**
Frontiers in Medicine **Associate Editor**
Journal of Taibah University for Science **Editor**
Biomedicines **Guest Editor**

Journals Served as Reviewer

Journal of Extracellular Vesicles, iMeta, Medcomm, Protein & Cell, Pharmacological Research, Cancer Letter, Laboratory Investigation, Phytomedicine, Analytical Cellular Pathology, Cell Cycle, Carcinogenesis, Frontiers in Genetics/Pharmacology/Oncology/Medicine, Therapeutic Advances in Gastroenterology, Liver International, Journal of Hepatocellular Carcinoma, Journal of Taibah University for Science

Presenting at the international conference

Speaker for the International Society of Extracellular Vesicles Annual Meeting (ISEV) 2024
Title: The elevated ECM1 protein in circulating sEVs is associated with integrin-β2, and it mediates the enhanced breast cancer growth and metastasis under obesity conditions
Speaker for The Consortium for Globalization of Chinese Medicine (CGCM) 2026
Title: sEV-PD-1-apigenin is a dual-action therapeutic that enhances immune activation and ECM1 degradation in the tumor microenvironment of Triple-negative breast cancer

個人履歷

徐渴陽，澳門科技大學中醫藥學院助理教授，博導。

1.人員簡介

於 2024 年獲香港浸會大學生物醫學與中醫學博士，悉尼大學訪問學者。曾就職於香港浸會大學中醫藥學院研究助理/研究實習員、杭州綠康康復醫院住院醫生。主要從事代謝性疾病及惡性腫瘤的中西醫結合基礎與臨床研究，包括中醫藥抗代謝、腫瘤的機制機理研究及其活性成分挖掘；基於多組學及細胞外囊泡探索代謝相關炎症、纖維化和惡性腫瘤的機制機理；開發細胞外囊泡靶向載藥系統。目前已發表 Molecular Cancer、Nature communications、Journal of Nanobiotechnology、 Pharmacological research、Cell death & diseases 等在內 SCI 論文 40 多篇。主持國家自然科學基金青年 C 類 1 項、澳門科技發展基金 2 項、澳門科技大學基金會課題 1 項，參與香港醫學健康研究基金、廣東省自然基金、浙江省自然基金等多個課題。曾獲 2024 國際細胞外囊泡協會年會青年研究員獎學金、香港浸會大學跨學科研究獎學金。現為世界中醫藥學會聯合會方藥量效研究專業委員會 常務理事、中國中醫藥資訊學會中醫臨床藥學分會 常務理事、世界中醫藥學會聯合會內分泌專業委員會 理事、 世界中醫藥學會聯合會中醫藥免疫專業委員會 理事、 The Good Practice in Traditional Chinese Medicine Research Association、Student Networks on EVs、Asia Pacific Societies for Extracellular Vesicles、America Society of Clinical Oncology、澳門高等教育發展促進會會員等，同時擔任國際期刊 Biomedicine 特刊編輯、Frontiers 多個系列雜誌副主編及 Journal of extracellular vesicles、Protein & cell、Pharmacological research、Cancer letters 等審稿人。

2.教育背景

2021.09-2024.10 香港浸會大學 哲學博士 （中醫學與生物醫學）師從呂愛平、關曉儀教授
2016.09-2019.06 浙江中醫藥大學 醫學碩士 中西醫結合臨床 師從包劍鋒、喬梁教授
2011.09-2016.06 成都中醫藥大學 醫學學士 中西醫結合臨床

3.研究經驗/工作經歷

2025 年 – 今 澳門科技大學中醫藥學院助理教授
2024.05-2024.11 澳大利亞悉尼大學，Storr liver centre 訪問學者

2021.09-2024.10 香港浸會大學深圳研究院 實習研究員
2020.09-2021.08 香港浸會大學 研究助理
2019.09-2020.08 浙江省杭州市濱江綠康康復醫院 住院醫師